Effect of different inhaled bronchodilators on recovery from methacholine-induced bronchoconstriction in asthmatic

A Quezada1, J Mallol, J Moreno

  • 1Department of Pediatrics, School of Medicine, University of Chile, Santiago, Chile.

Pediatric Pulmonology
|July 28, 1999
PubMed

Insights

Five inhaled asthma medications showed bronchodilator effects in children. Fenoterol and fenoterol with ipratropium bromide demonstrated significantly greater effects compared to other beta-agonist aerosols and placebo.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Pharmacology
  • Clinical Asthma Management

Background:

  • Mild to moderate asthma affects many children, necessitating effective bronchodilator therapies.
  • Metered dose inhaler (MDI) formulations are common delivery methods for asthma medications.
  • Understanding the comparative efficacy of different bronchodilators is crucial for optimal asthma control.

Purpose of the Study:

  • To evaluate the acute bronchodilator effects of five different metered dose inhaler (MDI) aerosol formulations in children with asthma.
  • To compare the efficacy of salbutamol, fenoterol, salbutamol with beclomethasone, fenoterol with ipratropium bromide, and salmeterol against a placebo.
  • To assess the bronchodilator response 5 minutes after inhalation.

Main Methods:

  • Two hundred fourteen children with mild to moderate asthma underwent methacholine bronchial challenge testing.
  • Participants were randomly assigned to receive one of six treatments: salbutamol, fenoterol, salbutamol + beclomethasone, fenoterol + ipratropium bromide, salmeterol, or placebo.
  • Bronchodilator effect was measured by forced expired volume in 1 second (FEV1) 5 minutes post-inhalation.

Main Results:

  • All five inhaled beta-agonist aerosols demonstrated a significant bronchodilator effect compared to placebo.
  • Fenoterol (F) and fenoterol + ipratropium bromide (F + IB) groups showed significantly greater bronchodilator effects (P < 0.05) than other formulations.
  • The study confirmed the ability of the tested aerosols to reverse methacholine-induced bronchoconstriction.

Conclusions:

  • Five different MDI aerosol formulations effectively reversed methacholine-induced bronchoconstriction in children with asthma within 5 minutes.
  • Fenoterol and fenoterol combined with ipratropium bromide exhibited superior bronchodilator efficacy among the tested beta-agonists.
  • These findings support the use of these bronchodilators for rapid relief of bronchoconstriction in pediatric asthma.

Related Concept Videos

Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: &#946;2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Methylxanthines01:24

Antiasthma Drugs: Methylxanthines

Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...